Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,582 GBX | -0.49% | -2.92% | +9.05% |
Apr. 17 | GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix | MT |
Apr. 17 | GSK: positive clinical results for gonorrhea | CF |
Sales 2024 * | 31.47B 39.25B | Sales 2025 * | 33.36B 41.61B | Capitalization | 64.97B 81.03B |
---|---|---|---|---|---|
Net income 2024 * | 5.63B 7.02B | Net income 2025 * | 6.27B 7.82B | EV / Sales 2024 * | 2.46 x |
Net Debt 2024 * | 12.33B 15.38B | Net Debt 2025 * | 9.21B 11.48B | EV / Sales 2025 * | 2.22 x |
P/E ratio 2024 * |
11.6
x | P/E ratio 2025 * |
10.2
x | Employees | 70,212 |
Yield 2024 * |
3.84% | Yield 2025 * |
4.11% | Free-Float | 92.58% |
Latest transcript on GSK plc
1 day | -0.03% | ||
1 week | -1.91% | ||
Current month | -6.94% | ||
1 month | -3.61% | ||
3 months | +0.91% | ||
6 months | +5.70% | ||
Current year | +9.64% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 18 M€ | +2.91% | - | |
2.51% | 5 M€ | +7.65% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 1,582 | -0.53% | 1 027 292 |
24-04-17 | 1,590 | -1.27% | 7,387,602 |
24-04-16 | 1,610 | -2.01% | 8,908,709 |
24-04-15 | 1,643 | 0.00% | 5,188,791 |
24-04-12 | 1,643 | +0.89% | 6,715,126 |
Delayed Quote London S.E., April 18, 2024 at 03:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.64% | 80.88B | |
+28.79% | 676B | |
+24.81% | 554B | |
-7.64% | 349B | |
+15.00% | 318B | |
+5.99% | 291B | |
+2.47% | 210B | |
-0.02% | 204B | |
-9.98% | 194B | |
-11.71% | 144B |
- Stock Market
- Equities
- GSK Stock